184
Participants
Start Date
July 17, 2024
Primary Completion Date
January 6, 2027
Study Completion Date
November 16, 2027
BMS-986470
Specified dose on specified days
Placebo
Specified dose on specified days
RECRUITING
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone, Marseille
NOT_YET_RECRUITING
Local Institution - 0032, Pittsburgh
RECRUITING
Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
RECRUITING
Inova Schar Cancer Institute, Fairfax
RECRUITING
Virginia Commonwealth University (VCU) Medical Center, Richmond
NOT_YET_RECRUITING
Local Institution - 0017, Atlanta
RECRUITING
University of Alabama at Birmingham, Birmingham
NOT_YET_RECRUITING
Local Institution - 0034, Chicago
ACTIVE_NOT_RECRUITING
Local Institution - 0001, Lenexa
RECRUITING
Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg
RECRUITING
Hôpital Universitaire Necker Enfants Malades, Paris
NOT_YET_RECRUITING
Local Institution - 0021, La Jolla
NOT_YET_RECRUITING
Local Institution - 0003, Oakland
RECRUITING
Yale-New Haven Hospital, New Haven
NOT_YET_RECRUITING
Local Institution - 0024, Boston
RECRUITING
Boston Medical Center, Boston
NOT_YET_RECRUITING
Local Institution - 0004, East Sussex
RECRUITING
King's College Hospital, London
NOT_YET_RECRUITING
Local Institution - 0005, Leeds
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY